Co-Diagnostics jumps as it expands South Asia distribution footprint

Co-Diagnostics, Inc. (CODX) is up 13.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a new company announcement expanding the commercial and distribution territory of its India-based joint venture, which investors may view as a step toward broader commercialization of its PCR product portfolio. The stock may also be benefiting from lingering momentum after recently resolving a Nasdaq listing compliance issue.

Details:

Co-Diagnostics announced an agreement to expand its CoSara Diagnostics joint venture territory to include Bangladesh, Pakistan, Nepal, and Sri Lanka.

The company said the expansion increases the South Asia addressable market to an estimated $13.0 billion and supports plans to commercialize the PCR Pro point-of-care instrument and the SARAGENE product line, subject to local regulatory approvals.

CoSara outlined go-to-market steps that include evaluating regulatory pathways, building distribution channels, and engaging regional distribution partners, with distributor outreach events planned for Q2 2026 and later in summer 2026.

Earlier this month, the company said it regained compliance with Nasdaq’s continued listing requirements and that its shares would resume trading on Nasdaq, reducing near-term delisting overhang.

Sources:

PRNewswire, U.S. Securities and Exchange Commission

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CODX Hedge Fund Activity

We have seen 13 institutional investors add shares of $CODX stock to their portfolio, and 21 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TOWER RESEARCH CAPITAL LLC (TRC) added 12,988 shares (+25976.0%) to their portfolio in Q4 2025, for an estimated $65,693
VANGUARD GROUP INC added 6,772 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $34,252
JANE STREET GROUP, LLC added 5,956 shares (+287.0%) to their portfolio in Q4 2025, for an estimated $30,125
HRT FINANCIAL LP removed 4,976 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,168
RENAISSANCE TECHNOLOGIES LLC removed 4,573 shares (-15.8%) from their portfolio in Q4 2025, for an estimated $23,130
GEODE CAPITAL MANAGEMENT, LLC added 4,305 shares (+40.4%) to their portfolio in Q4 2025, for an estimated $21,774
VIRTU FINANCIAL LLC removed 4,217 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $21,329

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CODX Analyst Ratings

Wall Street analysts have issued reports on $CODX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 10/28/2025

To track analyst ratings and price targets for $CODX, check out Quiver Quantitative's $CODX forecast page.

$CODX Price Targets

Multiple analysts have issued price targets for $CODX recently. We have seen 2 analysts offer price targets for $CODX in the last 6 months, with a median target of $2.25.

Here are some recent targets:

Jason McCarthy from Maxim Group set a target price of $1.5 on 11/26/2025
Jason Kolbert from D. Boral Capital set a target price of $3.0 on 10/28/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.